IL154008A0 - New pharmaceutical composition - Google Patents

New pharmaceutical composition

Info

Publication number
IL154008A0
IL154008A0 IL15400801A IL15400801A IL154008A0 IL 154008 A0 IL154008 A0 IL 154008A0 IL 15400801 A IL15400801 A IL 15400801A IL 15400801 A IL15400801 A IL 15400801A IL 154008 A0 IL154008 A0 IL 154008A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
new pharmaceutical
new
composition
pharmaceutical
Prior art date
Application number
IL15400801A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL154008(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL154008A0 publication Critical patent/IL154008A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15400801A 2000-07-28 2001-07-19 New pharmaceutical composition IL154008A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116393 2000-07-28
PCT/EP2001/008363 WO2002009815A2 (fr) 2000-07-28 2001-07-19 Nouvelle composition pharmaceutique

Publications (1)

Publication Number Publication Date
IL154008A0 true IL154008A0 (en) 2003-07-31

Family

ID=8169384

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15400801A IL154008A0 (en) 2000-07-28 2001-07-19 New pharmaceutical composition
IL154008A IL154008A (en) 2000-07-28 2003-01-16 Pharmaceutical preparations containing orlistat as a lipase inhibitor, processes for their production, kits containing them and their use in the preparation of drugs for the treatment and prevention of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154008A IL154008A (en) 2000-07-28 2003-01-16 Pharmaceutical preparations containing orlistat as a lipase inhibitor, processes for their production, kits containing them and their use in the preparation of drugs for the treatment and prevention of obesity

Country Status (37)

Country Link
US (5) US6756364B2 (fr)
EP (1) EP1307264B1 (fr)
JP (2) JP4265911B2 (fr)
KR (1) KR100572785B1 (fr)
CN (1) CN100423715C (fr)
AR (1) AR033548A1 (fr)
AT (1) ATE279961T1 (fr)
AU (2) AU2001289699B2 (fr)
BR (1) BR0112799B1 (fr)
CA (1) CA2416901C (fr)
CZ (1) CZ302087B6 (fr)
DE (1) DE60106623T2 (fr)
EC (1) ECSP034450A (fr)
EG (1) EG24357A (fr)
ES (1) ES2230362T3 (fr)
GT (1) GT200100152A (fr)
HR (1) HRP20030029B1 (fr)
HU (1) HU229292B1 (fr)
IL (2) IL154008A0 (fr)
JO (1) JO2320B1 (fr)
MA (1) MA26937A1 (fr)
ME (1) MEP90508A (fr)
MX (1) MXPA03000771A (fr)
MY (1) MY127247A (fr)
NO (1) NO330546B1 (fr)
NZ (1) NZ523684A (fr)
PA (1) PA8523201A1 (fr)
PE (1) PE20020336A1 (fr)
PL (1) PL204443B1 (fr)
PT (1) PT1307264E (fr)
RS (1) RS50397B (fr)
RU (1) RU2241462C2 (fr)
SI (1) SI1307264T1 (fr)
TW (1) TWI275395B (fr)
UY (1) UY26860A1 (fr)
WO (1) WO2002009815A2 (fr)
ZA (1) ZA200300456B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307263B1 (fr) * 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag Nouvelle application d'inhibiteurs de lipase
RU2241462C2 (ru) * 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US7083629B2 (en) 2001-05-30 2006-08-01 Satiety, Inc. Overtube apparatus for insertion into a body
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
KR100625399B1 (ko) * 2002-04-26 2006-09-20 에프. 호프만-라 로슈 아게 리파아제 억제제 및 글루코마난을 포함하는 약학 조성물
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
DK1545562T3 (da) * 2002-09-09 2006-08-21 Tno Forgrenede alfa-glucaner til vægtregulering
US7229428B2 (en) 2002-10-23 2007-06-12 Satiety, Inc. Method and device for use in endoscopic organ procedures
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
US6656194B1 (en) 2002-11-05 2003-12-02 Satiety, Inc. Magnetic anchoring devices
CA2811272C (fr) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US7591941B2 (en) * 2003-12-19 2009-09-22 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
US8828025B2 (en) 2004-02-13 2014-09-09 Ethicon Endo-Surgery, Inc. Methods and devices for reducing hollow organ volume
WO2006004574A2 (fr) * 2004-02-19 2006-01-12 Abbott Laboratories Methode d'utilisation de gamma cyclodextrine dans la regulation de la glycemie et de la secretion d'insuline
AU2005218318A1 (en) 2004-02-27 2005-09-15 Ethicon Endo-Surgery, Inc Methods and devices for reducing hollow organ volume
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
CA2561193A1 (fr) 2004-03-26 2005-10-20 Satiety, Inc. Systemes et methodes de traitement de l'obesite
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Procede de preparation d'un derive d'orlistat utile comme standard de reference dans la determination de la purete d'orlistat et procede de preparation d'orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
RU2283114C1 (ru) * 2005-06-07 2006-09-10 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы
ES2434072T3 (es) * 2005-06-09 2013-12-13 Norgine Bv Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona
CA2610922A1 (fr) * 2005-06-13 2006-12-21 Yeda Research And Development Co. Ltd. Utilisation d'allylmercaptocaptopril pour traiter ou prevenir l'obesite et des maladies associees a l'obesite
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
EP1945196A2 (fr) * 2005-11-08 2008-07-23 Genzyme Corporation POLYMERES CONTENANT DU MAGNESIUM POUR l'HYPERPHOSPHATEMIE
US8067402B2 (en) * 2005-12-12 2011-11-29 Allaccem, Inc. Methods and systems for coating an oral surface
EP1803714A1 (fr) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de formes cristallines de orlistat
WO2007086054A2 (fr) * 2006-01-25 2007-08-02 Yeda Research And Development Co. Ltd. Procede de preparation d’allylmercaptocaptopril (cpssa) et de disulfures asymetriques correspondants
DE602006004695D1 (de) * 2006-02-14 2009-02-26 Teva Pharma Pharmazeutische Zubereitungsform von aliphatischen amin-Polymeren und Verfahren zu deren Herstellung
CN101404982A (zh) * 2006-02-14 2009-04-08 特瓦制药工业有限公司 脂族胺聚合物的药物制剂和它们的制造方法
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
CA2749074A1 (fr) * 2006-09-01 2008-05-29 Usv Limited Procede de preparation d'hydrochlorure de sevelamer et formulation de celui-ci
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (fr) * 2006-10-24 2008-06-12 Thompson Md Ronald J Procédé et composition d'une herbe carminative ou d'un complément naturel permettant de diminuer les effets néfastes de l'orlistat, un inhibiteur de lipase oral, et un procédé avec des formulations permettant simultanément de réduire un risque de fracture et d'assurer
EP2124884B1 (fr) * 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions contenant des chelateurs d'acide biliaire pour le traitement des troubles oesphagiens
EP1944025A1 (fr) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables d'orlistat
CA2683383C (fr) 2007-02-21 2016-01-05 Allaccem, Incorporated Compositions a base de composes polycycliques pontes pour l'inhibition et le traitement de maladies
EP2565195B1 (fr) 2007-03-29 2015-05-06 Wyeth LLC Récepteur opioïde périphérique et son antagoniste ainsi que leurs utilisations
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
PL216542B1 (pl) * 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
CA2719134C (fr) 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
BRPI0918499A2 (pt) * 2008-09-02 2015-12-01 Usv Ltd polímeros reticulados
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
WO2010062861A2 (fr) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
WO2011075539A2 (fr) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Traitement de l'obésité ou du diabète avec des agents séquestrants des acides biliaires
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
WO2013049595A1 (fr) * 2011-09-29 2013-04-04 Ethicon Endo-Surgery, Inc. Procédés et compositions d'acides biliaires
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2591768B1 (fr) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Formulations de dose unitaire de sevelamer et des vitamines liposolubles et des tensioactifs
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
AU2013343565B2 (en) 2012-11-06 2018-07-26 Sigrid Therapeutics Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
EP2934495B1 (fr) 2012-12-21 2017-07-19 National Health Research Institutes Nanoparticules de silice mésoporeuse pour l'absorption d'huile
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
CN108601739B (zh) * 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
WO2017138878A1 (fr) 2016-02-09 2017-08-17 Albireo Ab Formulation orale de cholestyramine et utilisation associée
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法
WO2025207711A1 (fr) * 2024-03-27 2025-10-02 Mayo Foundation For Medical Education And Research Compositions d'inhibiteur de la lipase et méthodes de traitement de maladies

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
DE69633502T2 (de) 1995-12-26 2006-02-23 Suntory Ltd. Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
JP2002500183A (ja) 1998-01-09 2002-01-08 ジェルテックス ファーマシューティカルズ，インコーポレイテッド 脂肪結合性ポリマー
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
TR200100471T2 (tr) * 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
WO2000009123A1 (fr) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
WO2000013667A1 (fr) 1998-09-08 2000-03-16 Smithkline Beecham Corporation Comprimes a base de fibres solubles et d'un derive de lipstatine
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE60012301D1 (de) 1999-01-22 2004-08-26 Hunza Di Pistolesi Elvira & C Lipoproteinkomplexe und zusammensetzungen, die diese enthalten
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
RU2241462C2 (ru) * 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция

Also Published As

Publication number Publication date
DE60106623T2 (de) 2006-02-02
KR100572785B1 (ko) 2006-04-19
US6756364B2 (en) 2004-06-29
US20020035089A1 (en) 2002-03-21
US20040105838A1 (en) 2004-06-03
NO20030418D0 (no) 2003-01-27
HU229292B1 (en) 2013-10-28
EP1307264B1 (fr) 2004-10-20
JP2004505067A (ja) 2004-02-19
CZ2003582A3 (cs) 2004-02-18
RU2241462C2 (ru) 2004-12-10
US20100203032A1 (en) 2010-08-12
NZ523684A (en) 2005-04-29
DE60106623D1 (de) 2004-11-25
PA8523201A1 (es) 2002-10-24
US20060269510A1 (en) 2006-11-30
PT1307264E (pt) 2005-02-28
ES2230362T3 (es) 2005-05-01
GT200100152A (es) 2002-05-16
HRP20030029A2 (en) 2004-02-29
BR0112799B1 (pt) 2017-10-24
HRP20030029B1 (en) 2005-06-30
BR0112799A (pt) 2003-07-01
AU2001289699B2 (en) 2006-06-01
IL154008A (en) 2011-12-29
ZA200300456B (en) 2004-04-16
NO330546B1 (no) 2011-05-16
UY26860A1 (es) 2002-01-31
CN100423715C (zh) 2008-10-08
TWI275395B (en) 2007-03-11
JO2320B1 (en) 2005-09-12
EG24357A (en) 2009-03-04
MA26937A1 (fr) 2004-12-20
HK1058636A1 (zh) 2004-05-28
PE20020336A1 (es) 2002-05-08
US20050136030A1 (en) 2005-06-23
JP2009073833A (ja) 2009-04-09
CA2416901C (fr) 2007-07-03
HUP0301281A2 (hu) 2003-08-28
RS50397B (sr) 2009-12-31
WO2002009815A2 (fr) 2002-02-07
ATE279961T1 (de) 2004-11-15
MXPA03000771A (es) 2003-06-04
CA2416901A1 (fr) 2002-02-07
JP4265911B2 (ja) 2009-05-20
WO2002009815A3 (fr) 2002-04-18
AR033548A1 (es) 2003-12-26
ME00671B (fr) 2011-12-20
NO20030418L (no) 2003-01-27
HUP0301281A3 (en) 2005-05-30
CZ302087B6 (cs) 2010-10-06
PL366105A1 (en) 2005-01-24
MY127247A (en) 2006-11-30
MEP90508A (en) 2011-12-20
YU5003A (sh) 2006-01-16
AU8969901A (en) 2002-02-13
US8071571B2 (en) 2011-12-06
PL204443B1 (pl) 2010-01-29
CN1444495A (zh) 2003-09-24
KR20030029796A (ko) 2003-04-16
ECSP034450A (es) 2003-03-10
EP1307264A2 (fr) 2003-05-07
SI1307264T1 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
EG24357A (en) New Pharmaceutical composition
IL152659A0 (en) Pharmaceutical composition
SI1524266T1 (sl) Farmacevtski sestavek
GB2358582B (en) Pharmaceutical compositions
HUP0204555A3 (en) Pharmaceutical composition
HUP0300582A3 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
HUP0400553A3 (en) Pharmaceutical compositions
IL154238A0 (en) Pharmaceutical composition
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
GB0005382D0 (en) Pharmaceutical composition
AU8254101A (en) Medicinal compositions
GB0101094D0 (en) Pharmaceutical composition
GB0002691D0 (en) Pharmaceutical composition
GB0019599D0 (en) Pharmaceutical composition
GB0026716D0 (en) Pharmaceutical composition
GB0006301D0 (en) Pharmaceutical composition
GB0027375D0 (en) Pharmaceutical composition
GB0016684D0 (en) Pharmaceutical composition
GB0018321D0 (en) Pharmaceutical compositions
HU0700204D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions